| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bio-Rad Laboratories, Inc.$325.48
-1.24 (-0.38%)
F 17Pipeline Score Tools & Services · Commercial
Market Cap
7.75 B
EPS
6.11
P/E Ratio
47.37 $
Value Trade
99.51 M
SEC Financials
Q1 2026Dilution Risk
Revenue
592.10 M
R&D Expenses
62.90 M
Operating CF
108.10 M
Total Assets
9.79 B
Total Liabilities
2.94 B
Equity
6.85 B
D/E Ratio
12,345
15.81 %
Week
-6.43 %
1 Month
6.57 %
3 Month
-5.23 %
6 Month
-52.22 %
5 Year
11,159.22 %
All Time
Cash Data
Cash Position
1.56 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
190.10 K
52 Week Range
211.43 - 343.12
% held by Insiders
33.2 %
% held by Institutions
74.29 %
Enterprise Value
7.56 B
Total Shares
21.70 M
Short %
8.62 %
Float Shares
18.10 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 17%
Small Cap (rank 759 of 913)
Percentile RankBio-Rad Laboratories, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BIOBio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
Bio-Rad Laboratories, Inc. will announce its second-quarter 2026 financial results on August 4, 2026. The report will be released after market close, followed by a conference call at 2:00 PM PT. This engagement allows stakeholders to discuss the results directly with management.
Read more →BIOBio-Rad to Participate in Upcoming Investor Conferences
Bio-Rad is set to participate in upcoming investor conferences, indicating its ongoing engagement with investors. The participation may provide insights into the company's strategies and future directions. However, specific details about the conferences or presentations were not disclosed in the article.
Read more →BIOBio-Rad Reports First-Quarter 2026 Financial Results
Bio-Rad Laboratories, Inc. reported its first-quarter 2026 financial results, showing a 1.1% increase in net sales year-over-year, despite facing external challenges. The company experienced a significant net loss of $527.1 million, primarily due to changes in the fair market value of its investments. Additionally, Bio-Rad updated its full-year financial outlook, anticipating a potential revenue decline.
Read more →BIOBio-Rad Reports First -Quarter 2026 Financial Results
Bio-Rad Laboratories, Inc. announced its financial results for the first quarter of 2026, showing a modest revenue growth of 1.1% year-over-year despite facing external market headwinds. Although the company generated strong operating cash flow and completed a significant share repurchase, it also reported a net loss of $527.1 million, attributed to changes in the fair market value of its investments. Both Life Science and Clinical Diagnostics segments experienced declines in currency-neutral sales, leading to a revised financial outlook for the full year indicating potential revenue decreases.
Read more →BIOBio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
Bio-Rad Laboratories, Inc. will announce its first-quarter 2026 financial results on April 30, 2026. A conference call is scheduled for the same day at 2:00 PM PT to discuss these results. Investors can participate via phone or a live webcast, with a replay available for a year. Bio-Rad is known for its innovative products in life sciences and diagnostics.
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
Bio-Rad Laboratories, Inc. announced its financial results for Q4 and the full year of 2025, reporting modest revenue growth but lower gross and operating margins than anticipated. The company successfully integrated its recent acquisition, Stilla Technologies, into its product offerings, contributing to growth in its digital PCR segment. However, challenges in the Life Science segment and geopolitical uncertainties affected overall market conditions. Looking ahead, Bio-Rad anticipates moderate revenue growth for 2026.
Read more →BIOBio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
Bio-Rad Laboratories, Inc. will announce its financial results for Q4 and the full year 2025 on February 12, 2026. A conference call is scheduled for 2:00 PM PT to discuss these results. The company continues to operate as a leader in life science and clinical diagnostics, serving various sectors.
Read more →BIOBio-Rad Reports Third -Quarter 2025 Financial Results
Bio-Rad Laboratories, Inc. announced its financial results for the third quarter ending September 30, 2025. The company reported a slight increase in net sales but faced significant GAAP net losses primarily due to investment evaluations. Non-GAAP results showed growth in income, but overall demand for products has been affected by ongoing challenges in the biotech sector. Full-year financial outlook remains unchanged, forecasting modest growth.
Read more →BIOBio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away
Alice N. Schwartz, co-founder and Director Emeritus of Bio-Rad Laboratories, passed away at 99 on September 25, 2025. Schwartz, who co-founded the company in 1952 with her husband, played a significant role in developing Bio-Rad's first diagnostic test kit. She remained active within the company until 2022, inspiring generations of scientists and contributing greatly to Bio-Rad's legacy in life science research and diagnostics.
Read more →BIOBio-Rad Reports Second -Quarter 2025 Financial Results
Bio-Rad Laboratories, Inc. reported its second-quarter 2025 financial results, showcasing a revenue increase of 2.1% year-over-year. The company recorded a significant net income of $317.8 million, recovering from a net loss in the same period last year. Key contributors to this growth included higher sales in the Life Science segment and the acquisition of Stilla Technologies, enhancing their product portfolio. However, the Clinical Diagnostics segment faced challenges, particularly due to reduced reimbursements for diabetes testing in China.
Read more →BIOBio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
Bio-Rad Laboratories has appointed Rajat Mehta as the new Executive Vice President of Global Commercial Operations, effective August 4, 2025. Mehta succeeds Mike Crowley, who is retiring after 26 years with the company. With a strong background in the biopharmaceutical and diagnostics sectors, Mehta previously held senior leadership roles at Labcorp and Thermo Fisher Scientific. Bio-Rad's leadership anticipates that Mehta's expertise will contribute significantly to the company's ongoing strategy and growth in the commercial sector.
Read more →BIOBio-Rad Reports First -Quarter 2025 Financial Results
Bio-Rad Laboratories, Inc. has reported its financial results for the first quarter of 2025, highlighting a decrease in total revenue of 4.2% compared to the same period in 2024. The company's net income has sharply fallen from $383.9 million to $64.0 million, attributed to lower sales in its Life Science segment and challenges in the academic research market. Bio-Rad has adjusted its full-year 2025 outlook, expecting revenue to range from a decline of 1.0% to a growth of 1.5%. Despite these challenges, the company remains committed to its growth initiatives and improving operational margins.
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
Bio-Rad Laboratories, Inc. reported its fourth-quarter and full-year financial results for 2024, indicating a decrease in sales driven primarily by challenges in the Life Science segment. While the Clinical Diagnostics business showed slight growth, the overall financial performance reflected a net loss largely attributed to investment value changes. The company plans to enhance its product portfolio through the anticipated acquisition of Stilla Technologies and aims for continued margin expansion amid ongoing challenges.
Read more →BIOBio-Rad Reports Third-Quarter 2024 Financial Results
Bio-Rad Laboratories, Inc. reported its third-quarter financial results for 2024, showing net sales of $649.7 million, a 2.8% increase compared to the prior year, primarily driven by the Clinical Diagnostics segment. However, the Life Science segment experienced a slight decline of 1.0%. The company's gross margin improved, reaching 54.8%, while overall income from operations saw a decrease from the previous year. Despite challenges in the biotech market, Bio-Rad remains optimistic about future growth with new leadership in place.
Read more →BIOBio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
Bio-Rad Laboratories, Inc. has appointed Jon DiVincenzo as President and Chief Operating Officer, effective September 9, 2024. He will replace Andy Last, who is retiring. DiVincenzo previously held leadership roles at Labcorp Holdings and PerkinElmer, bringing over thirty years of experience in the life sciences and clinical diagnostics sectors. His appointment is expected to support Bio-Rad's ongoing growth and transformational goals.
Read more →BIOBio-Rad Reports Second-Quarter 2024 Financial Results
Bio-Rad Laboratories reported its financial results for the second quarter of 2024, revealing a 6.3% decline in total net sales compared to the previous year, driven largely by a 16.5% decrease in the Life Science segment. While the Clinical Diagnostics segment saw a slight increase in sales, the overall results were impacted by a substantial net loss driven by the change in market value of investments. The company has adjusted its full-year revenue outlook downward, anticipating a decline instead of growth. Despite challenges, management remains optimistic about margins improving due to ongoing supply chain initiatives and cost control measures.
Read more →BIOBio-Rad Reports First-Quarter 2024 Financial Results
Bio-Rad Laboratories, Inc. reported a total net sales of $610.8 million for the first quarter of 2024, reflecting a 9.8% decrease compared to the previous year. The Life Science segment experienced a significant decline in sales, dropping by 25.3%, primarily influenced by market weaknesses in biotech and biopharma. In contrast, the Clinical Diagnostics segment grew by 4.7%, driven by higher demand for quality control and diabetes products. Despite challenges, management expressed cautious optimism for a recovery in the biopharma markets later this year.
Read more →BIOBio-Rad Announces Life Science Group Management Changes
Bio-Rad Laboratories, Inc. has announced the promotion of James J. Barry to Executive Vice President and President of the Life Science Group, effective May 1, 2024. Barry succeeds Dr. Simon May, who is leaving the company for another professional opportunity. With experience in global manufacturing and quality systems, Barry is positioned to lead the life science division effectively. Bio-Rad operates as a leader in life science research and clinical diagnostics, focusing on innovative products for diverse clients worldwide.
Read more →BIOBio-Rad's Chief Operating Officer Andrew Last to Retire
Bio-Rad Laboratories announced the upcoming retirement of Chief Operating Officer Dr. Andrew Last, effective by early September 2024. Dr. Last, who joined the company in April 2019, will assist in the transition while a successor is identified. His leadership has been pivotal in driving operational improvements and navigating macroeconomic challenges, positioning Bio-Rad for continued growth. The company, known for its contributions to life sciences and clinical diagnostics, remains committed to innovation.
Read more →BIOBio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
Bio-Rad Laboratories, Inc. has announced the appointment of Roop K. Lakkaraju as Executive Vice President and Chief Financial Officer, effective April 15, 2024. Lakkaraju previously served as CFO at Benchmark Electronics and has held senior financial roles in various multinational companies. The current CEO, Norman Schwartz, expressed confidence in Lakkaraju's ability to significantly contribute to the company's financial strategy and development. His appointment is viewed as a positive move for the company's operational and financial initiatives.
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
Bio-Rad Laboratories reported its fourth-quarter and full-year 2023 financial results, revealing a total net sales decrease of 6.7% for Q4 compared to the previous year. The Life Science segment particularly struggled, with a decline of 19.1%, while the Clinical Diagnostics segment saw a modest increase of 5.3%. The company recognized challenges in biopharma markets, and despite reporting a net loss of $637.3 million for the full year, it remains hopeful for a gradual recovery in 2024 driven by ongoing initiatives.
Read more →BIOBio-Rad Reports Third-Quarter 2023 Financial Results
Bio-Rad Laboratories, Inc. reported third-quarter 2023 financial results, revealing a decrease in total net sales to $632.1 million, down 7.1% from the previous year. The Life Science segment experienced a notable decline of 17.1% in sales, while the Clinical Diagnostics segment saw a slight increase of 1.7%. The company has amended its full-year revenue outlook, now anticipating a decline of approximately 3.5% compared to earlier expectations of growth. Despite these challenges, the company's net income stands at $106.3 million, showing recovery from a net loss in the same quarter last year.
Read more →BIOBio-Rad Reports Second-Quarter 2023 Financial Results
Bio-Rad Laboratories reported its second-quarter 2023 financial results, revealing a net sales decrease of 1.4% year-over-year, mainly influenced by a significant drop in COVID-related sales. Despite an overall decline, the Clinical Diagnostics segment showed growth, with a revenue increase of 3.3%. The company also acknowledged a net loss of $1,162.3 million for the quarter, influenced by the recognition of changes in the fair market value of equity securities. Additionally, Bio-Rad updated its 2023 financial outlook, now expecting lower non-GAAP currency-neutral revenue growth of approximately 0.8%.
Read more →BIOBio-Rad Reports First-Quarter 2023 Financial Results HERCULES, Calif.
Bio-Rad Laboratories, Inc. has reported its financial results for the first quarter of 2023, revealing a 3.3% decrease in net sales compared to the same quarter last year. However, excluding COVID-related sales, there was a notable 6.1% increase in revenue, largely driven by strong performance in its Life Science products. Despite a decline in margins and net sales, the company expressed confidence in the resilience of its core business segments. Bio-Rad has also updated its financial outlook for 2023, lowering expected growth projections.
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results
Bio-Rad Laboratories, Inc. reported its fourth-quarter and full-year 2022 financial results, indicating a net income of $827.7 million for Q4 2022, reversing a significant loss from Q4 2021. The Life Science segment showed a healthy growth of 10.1% in sales, while the Clinical Diagnostics segment experienced an 8.7% drop year-over-year. Overall, total net sales for the full year decreased by 4.1% due to a decline in COVID-related revenues, despite gross margins remaining relatively stable. The company remains optimistic about future growth through operational improvements and innovation.
Read more →BIOBio-Rad Reports Third-Quarter 2022 Financial Results
Bio-Rad Reports Third-Quarter 2022 Financial Results HERCULES, Calif.-October 27, 2022 -- Bio-Rad Laboratories, Inc. (NYSE BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the third quarter ended Sept
Read more →BIOBio-Rad Reports Second-Quarter 2022 Financial Results HERCULES, Calif.
Bio-Rad Reports Second-Quarter 2022 Financial Results HERCULES, Calif.-- July 28, 2022 -- Bio-Rad Laboratories, Inc. (NYSE BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended Jun
Read more →BIOBio-Rad Reports First-Quarter 2022 Financial Results
Bio-Rad Reports First-Quarter 2022 Financial Results HERCULES, Calif.-April 28, 2022-Bio-Rad Laboratories, Inc. (NYSE BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31,
Read more →BIOBio-Rad Announces Closing of $1.2 Billion Aggregate Senior Notes Offering
Bio-Rad Announces Closing of $1.2 Billion Aggregate Senior Notes Offering HERCULES, California March 2, 2022 Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today the closing of its underwritt
Read more →BIO▲ +7.2%on this newsshared move
F E B R U A R Y 2 5 , 2 0 2 2 Bio-Rad Investor Laboratories, Inc. Day 2022 Forward-Looking Statements & Use of Non-GAAP Reporting Forward-looking Statements. Some statements in this presentation may be forward-looking st
F E B R U A R Y 2 5 , 2 0 2 2 Bio-Rad Investor Laboratories, Inc. Day 2022 Forward-Looking Statements & Use of Non-GAAP Reporting Forward-looking Statements. Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Liti
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2021 Financial Results
Bio-Rad Reports Fourth-Quarter and Full-Year 2021 Financial Results HERCULES, Calif.-February 10, 2022-Bio-Rad Laboratories, Inc. (NYSE BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quar
Read more →BIOBio-Rad Reports Third-Quarter 2021 Financial Results
Bio-Rad Reports Third-Quarter 2021 Financial Results HERCULES, Calif.-October 28, 2021-Bio-Rad Laboratories, Inc. (NYSE BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended Septemb
Read more →BIOBio-Rad Reports Second-Quarter 2021 Financial Results
Bio-Rad Reports Second-Quarter 2021 Financial Results HERCULES, Calif.-July 29, 2021-Bio-Rad Laboratories, Inc. (NYSE BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30,
Read more →BIOBio-Rad Reports First-Quarter 2021 Financial Results
Bio-Rad Reports First-Quarter 2021 Financial Results HERCULES, Calif.-April 29, 2021-Bio-Rad Laboratories, Inc. (NYSE BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31,
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2020 Financial Results
Bio-Rad Reports Fourth-Quarter and Full-Year 2020 Financial Results HERCULES, Calif.-February 11, 2021-Bio-Rad Laboratories, Inc. (NYSE BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quar
Read more →BIOOUTLOOK: 2021 - 2023 Bio-Rad Laboratories, Inc.
FORWARD-LOOKING STATEMENTS & USE OF NON-GAAP REPORTING Forward-looking Statements. Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regardi
Read more →BIOBio-Rad Reports Third-Quarter 2020 Financial Results
Bio-Rad Reports Third-Quarter 2020 Financial Results HERCULES, Calif.-October 29, 2020-Bio-Rad Laboratories, Inc. (NYSE BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended Septemb
Read more →BIOBio-Rad Reports Second-Quarter 2020 Financial Results
Bio-Rad Reports Second-Quarter 2020 Financial Results HERCULES, Calif.-July 30, 2020-Bio-Rad Laboratories, Inc. (NYSE BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30,
Read more →BIOBio-Rad Reports First-Quarter 2020 Financial Results
Bio-Rad Reports First-Quarter 2020 Financial Results HERCULES, Calif.-May 6, 2020-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results
Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results HERCULES, Calif.- February 13, 2020-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth qu
Read more →BIOBio-Rad Reports Third-Quarter 2019 Financial Results
Bio-Rad Reports Third-Quarter 2019 Financial Results HERCULES, Calif.-October 31, 2019-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended Septem
Read more →BIOCorrected Press Release Bio-Rad Reports Second-Quarter 2019 Financial Results
Corrected Press Release Bio-Rad Reports Second-Quarter 2019 Financial Results HERCULES, Calif. August 27, 2019 This press release corrects a prior version published on August 1, 2019. The prior press release contained a $3.37 million error with respect to Legal Matters used in
Read more →BIOBio-Rad Reports Second-Quarter 2019 Financial Results
Bio-Rad Reports Second-Quarter 2019 Financial Results HERCULES, Calif.-August 1, 2019-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 3
Read more →BIOBio-Rad Reports First Quarter 2019 Financial Results
Bio-Rad Reports First Quarter 2019 Financial Results HERCULES, Calif.-May 8, 2019-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2
Read more →BIOBio-Rad Appoints Andrew Last as Executive Vice President and Chief Operating Officer
Bio-Rad Appoints Andrew Last as Executive Vice President and Chief Operating Officer HERCULES, Calif. April 22, 2019 Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dr
Read more →BIOBio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer
Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer HERCULES, California. April 2, 2019 Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the appointment of
Read more →BIOBio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing
Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form HERCULES, California. - March 25, 2019 Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received a
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2018 Financial Results
Bio-Rad Reports Fourth-Quarter and Full-Year 2018 Financial Results HERCULES, Calif.-February 28, 2019-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth qua
Read more →BIOChristine Tsingos Announces Plans to Retire as CFO of Bio-Rad Laboratories, Inc. Effective
Christine Tsingos Announces Plans to Retire as CFO of Bio-Rad Laboratories, Inc. Effective April 30, 2019 HERCULES, Calif. January 3, 2019 Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced
Read more →BIOBio-Rad Reports Third-Quarter 2018 Financial Results
Bio-Rad Reports Third-Quarter 2018 Financial Results HERCULES, Calif.-November 1, 2018-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended Septem
Read more →BIOBio-Rad Reports Second-Quarter 2018 Financial Results
Bio-Rad Reports Second-Quarter 2018 Financial Results HERCULES, Calif.-August 7, 2018-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 3
Read more →BIOBio-Rad Reports First Quarter 2018 Financial Results
Bio-Rad Reports First Quarter 2018 Financial Results HERCULES, Calif.-May 8, 2018-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2017 Financial Results
Bio-Rad Reports Fourth-Quarter and Full-Year 2017 Financial Results HERCULES, Calif.-February 27, 2018-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth qua
Read more →BIOBio-Rad Authorizes New $250 Million Share Repurchase Program
Bio-Rad Authorizes New $250 Million Share Repurchase Program HERCULES, Calif.-November 28, 2017-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that its board of directors has authorize
Read more →BIOBio-Rad Reports Third-Quarter 2017 Financial Results
Bio-Rad Reports Third-Quarter 2017 Financial Results HERCULES, Calif.- November 2, 2017-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended Sep
Read more →BIOBio-Rad Reports Second-Quarter 2017 Financial Results
Bio-Rad Reports Second-Quarter 2017 Financial Results HERCULES, Calif.- August 3, 2017-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the second quarter ended Jun
Read more →BIOBio-Rad Reports First-Quarter 2017 Financial Results
Bio-Rad Reports First-Quarter 2017 Financial Results HERCULES, Calif.- May 4, 2017-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results
Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results HERCULES, Calif.-February 23, 2017-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced financial results for the fourth q
Read more →BIOTO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF THE COMMON STOCK OF BIO-RAD LABORATORIES, INC. ( BIO-RAD OR THE COMPANY ) AS OF NOVEMBER 4, 2016 (THE RECORD DATE ) PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. T
PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL OF THE ABOVE-CAPTIONED SHAREHOLDER DERIVATIVE ACTION (THE ACTIONS ) AND CONTAINS IMPORTANT INFORMATION REGARDING YOUR RIGHTS. YOUR RIGHTS MAY BE AFFECTED BY THESE LE
Read more →BIOBio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent
Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent HERCULES, Calif.-November 1, 2016-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the
Read more →BIOBio-Rad Reports Second-Quarter 2016 Financial Results
Bio-Rad Reports Second-Quarter 2016 Financial Results HERCULES, Calif.-August 3, 2016-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June
Read more →BIOBio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of nearly 4 Percent HERCULES, CA
Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of nearly 4 Percent HERCULES, CA - May 5, 2016 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today fo
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2015 Financial Results
Bio-Rad Reports Fourth-Quarter and Full-Year 2015 Financial Results HERCULES, Calif.-February 25, 2016-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced financial results for the fourth q
Read more →BIOBio-Rad Reports Third-Quarter 2015 Financial Results HERCULES, CA
Bio-Rad Reports Third-Quarter 2015 Financial Results HERCULES, CA - November 3, 2015 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended Sept
Read more →BIOBio-Rad Reports Second-Quarter 2015 Financial Results HERCULES, CA
Bio-Rad Reports Second-Quarter 2015 Financial Results HERCULES, CA - August 6, 2015 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June
Read more →BIOBio-Rad Reports First-Quarter 2015 Financial Results HERCULES, CA
Bio-Rad Reports First-Quarter 2015 Financial Results HERCULES, CA - May 5, 2015 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31,
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2014 Financial Results HERCULES, CA
Bio-Rad Reports Fourth-Quarter and Full-Year 2014 Financial Results HERCULES, CA - February 26, 2015 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the fourth q
Read more →BIOBio-Rad Reports Third-Quarter 2014 Financial Results HERCULES, CA
Bio-Rad Reports Third-Quarter 2014 Financial Results HERCULES, CA - November 4, 2014 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for t
Read more →BIOBio-Rad Laboratories Resolves Foreign Corrupt Practices Act Matters with U.S. Government Fully Settles DOJ and SEC Investigations Regarding International Operations from 2005-2010 Government Acknowledges Bi
Bio-Rad Laboratories Resolves Foreign Corrupt Practices Act Matters with U.S. Government Fully Settles DOJ and SEC Investigations Regarding International Operations from 2005-2010 Government Acknowledges Bio-Rad for Self-Reporting and Thorough Remedial Actions HERCULES, CA Nov
Read more →BIOBio-Rad Appoints John Goetz as Chief Operating Officer and Announces Other Executive Appointments HERCULES, CA
Bio-Rad Appoints John Goetz as Chief Operating Officer and Announces Other Executive Appointments HERCULES, CA - October 1, 2014 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostics products, today announced the r
Read more →BIOBio-Rad Reports Second-Quarter 2014 Financial Results HERCULES, CA
Bio-Rad Reports Second-Quarter 2014 Financial Results HERCULES, CA - August 5, 2014 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June
Read more →BIOBio-Rad Announces the Appointment of New Board Member HERCULES, CA
Bio-Rad Announces the Appointment of New Board Member HERCULES, CA - July 25, 2014 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostics products, announced today that Joel McComb has been appointed to its Board of
Read more →BIOBio-Rad Reports First-Quarter 2014 Financial Results HERCULES, CA
Bio-Rad Reports First-Quarter 2014 Financial Results HERCULES, CA - May 6, 2014 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the first qua
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2013 Financial Results HERCULES, CA
Bio-Rad Reports Fourth-Quarter and Full-Year 2013 Financial Results HERCULES, CA - February 27, 2014 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global manufacturer and distributor of life science research and clinical diagnostic products, announced financial results to
Read more →BIOBio-Rad Reports Third-Quarter 2013 Financial Results HERCULES, CA
Bio-Rad Reports Third-Quarter 2013 Financial Results HERCULES, CA - November 7, 2013 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for t
Read more →BIOBio-Rad Reports Second-Quarter 2013 Financial Results HERCULES, CA
Bio-Rad Reports Second-Quarter 2013 Financial Results HERCULES, CA - August 6, 2013 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for th
Read more →BIOBio-Rad Reports First-Quarter 2013 Financial Results HERCULES, CA
Bio-Rad Reports First-Quarter 2013 Financial Results HERCULES, CA - May 7, 2013 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the fi
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2012 Financial Results HERCULES, CA
Bio-Rad Reports Fourth-Quarter and Full-Year 2012 Financial Results HERCULES, CA - February 26, 2013 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial res
Read more →BIOBio-Rad Reports Third-Quarter 2012 Financial Results HERCULES, CA
Bio-Rad Reports Third-Quarter 2012 Financial Results HERCULES, CA - November 6, 2012 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for t
Read more →BIOBio-Rad Reports Second-Quarter 2012 Financial Results HERCULES, CA
Bio-Rad Reports Second-Quarter 2012 Financial Results HERCULES, CA - August 7, 2012 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for th
Read more →BIOBio-Rad Reports First-Quarter 2012 Financial Results HERCULES, CA
Bio-Rad Reports First-Quarter 2012 Financial Results HERCULES, CA - May 1, 2012 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the fi
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2011 Financial Results HERCULES, CA
Bio-Rad Reports Fourth-Quarter and Full-Year 2011 Financial Results HERCULES, CA - February 23, 2012 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial res
Read more →BIOBio-Rad Reports Third-Quarter Revenue Growth of More Than 9 Percent HERCULES, CA
Bio-Rad Reports Third-Quarter Revenue Growth of More Than 9 Percent HERCULES, CA - November 1, 2011 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial resu
Read more →BIOBio-Rad Reports Second-Quarter Revenue Growth of 11.5 Percent HERCULES, CA
Bio-Rad Reports Second-Quarter Revenue Growth of 11.5 Percent HERCULES, CA - August 2, 2011 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results toda
Read more →Competitive Position
How BIO ranks across every disease it competes inCompetitive Position is a premium feature
See how BIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial